Institute of Human Nutrition, University of Southampton, Southampton, UK.
Intensive Care Med. 2010 May;36(5):735-49. doi: 10.1007/s00134-009-1744-5. Epub 2010 Jan 14.
Energy deficit is a common and serious problem in intensive care units and is associated with increased rates of complications, length of stay, and mortality. Parenteral nutrition (PN), either alone or in combination with enteral nutrition, can improve nutrient delivery to critically ill patients. Lipids provide a key source of calories within PN formulations, preventing or correcting energy deficits and improving outcomes.
In this article, we review the role of parenteral lipid emulsions (LEs) in the management of critically ill patients and highlight important biologic activities associated with lipids. Soybean-oil-based LEs with high contents of polyunsaturated fatty acids (PUFA) were the first widely used formulations in the intensive care setting. However, they may be associated with increased rates of infection and lipid peroxidation, which can exacerbate oxidative stress. More recently developed parenteral LEs employ partial substitution of soybean oil with oils providing medium-chain triglycerides, omega-9 monounsaturated fatty acids or omega-3 PUFA. Many of these LEs have demonstrated reduced effects on oxidative stress, immune responses, and inflammation. However, the effects of these LEs on clinical outcomes have not been extensively evaluated.
Ongoing research using adequately designed and well-controlled studies that characterize the biologic properties of LEs should assist clinicians in selecting LEs within the critical care setting. Prescription of PN containing LEs should be based on available clinical data, while considering the individual patient's physiologic profile and therapeutic requirements.
能量不足是重症监护病房中常见且严重的问题,与并发症发生率增加、住院时间延长和死亡率升高有关。肠外营养(PN)单独或与肠内营养联合使用可以改善危重患者的营养供应。脂肪是 PN 配方中热量的主要来源,可预防或纠正能量不足并改善预后。
本文综述了肠外脂肪乳剂(LE)在危重症患者管理中的作用,并强调了与脂肪相关的重要生物学活性。富含多不饱和脂肪酸(PUFA)的大豆油基 LE 是重症监护环境中最早广泛使用的制剂。然而,它们可能与感染和脂质过氧化增加有关,这会加重氧化应激。最近开发的肠外 LE 采用部分替代大豆油,用提供中链甘油三酯、ω-9 单不饱和脂肪酸或 ω-3 PUFA 的油。这些 LE 中的许多已被证明对氧化应激、免疫反应和炎症的影响较小。然而,这些 LE 对临床结局的影响尚未得到广泛评估。
使用充分设计和严格控制的研究来描述 LE 的生物学特性的持续研究应有助于临床医生在重症监护环境中选择 LE。含有 LE 的 PN 处方应基于现有临床数据,同时考虑患者的个体生理状况和治疗需求。